9 Jan 2022
Laekna Therapeutics and Innovent Biologics obtain IND approval for combination therapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors
Author: admintech | Filed under: Press ReleaseSHANGHAI, China and WARREN, N.J., Jan. 9, 2022 /PRNewswire/ — Today, Laekna Therapeutics announced that the investigational new drug (IND) application of a combination therapy for the phase 1/2 clinical trial in patients with solid tumors who have been refractory to treatment with…